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Background: Studies have suggested that the 2nd generation XIENCE V everolimus-eluting stent (EES) might reduce stent thrombosis (ST) 
compared to the 1st TAXUS paclitaxel-eluting stent (PES), but no individual trial has been adequately powered to examine the incidence, timing and 
predictors of ST. We therefore analysed ST rates and distribution during the two years after EES compared to PES from a large pooled-database of 4 
randomised trials.
Methods: Baseline clinical, angiographic and procedural data from the SPIRIT II, III, IV and COMPARE trials, each of which assigned pts to EES vs. 
PES, were pooled in a database of 6,788 randomized patients (pts). Early (0-30 days), late (30 days-1 yr) and very late (1 yr-2 yr) ARC defined ST 
rates were calculated using Kaplan-Meier methods and compared with the log-rank test.
Results: As shown in the Table, EES compared to PES significantly reduced the rates of early, late, very late and overall ST at 2 years, as well as 
composite cardiac death or MI. The 2 year cardiac death or MI rate was 95.0% in pts with definite or probable (def/prob) ST compared to 3.8% 
without def/prob ST (p<0.0001).
Conclusions: In this large pooled analysis from 4 randomized trials, EES resulted in a 70% reduction in the rate of ST at 2 years compared to PES. 
This reduction was due to significantly lower rates of early, late and very late ST with EES. Lower ST rates with EES compared to PES were a major 
contributor to the 40% reduction in the composite rate of cardiac death or MI at 2 years with EES. 
ST, all (0-730 d)
EES (%)
(n=4247)
PES (%)
(n=2541)
HR (95% C.I.) p-value 
ARC Def 0.5 1.6 0.30 [0.18,0.52] <0.0001
ARC Prob 0.2 0.8 0.25 [0.11,0.57] 0.0004
ARC Def/Prob 0.7 2.3 0.30 [0.19,0.47] <0.0001
Early ST (0-30 d)
ARC Def 0.2 0.8 0.28 [0.13,0.63] 0.0009
ARC Prob 0.0 0.2 N/A 0.002
ARC Def/Prob 0.2 1.0 0.21 [0.10,0.46] <0.0001
Late ST (30-365 d)
ARC Def 0.1 0.4 0.30 [0.10,0.87] 0.02
ARC Prob 0.1 0.2 0.48 [0.13,1.77] 0.26
ARC Def/Prob 0.2 0.6 0.38 [0.17,0.88] 0.02
Very Late ST (365-730 d)
ARC Def 0.2 0.5 0.32 [0.12,0.87] 0.02
ARC Prob 0.1 0.3 0.30 [0.09,0.99] 0.04
ARC Def/Prob 0.3 0.8 0.31 [0.14,0.67] 0.002
Cardiac Death/MI (0-730 d) 4.0 6.6 0.60 [0.48,0.74] <0.0001
